B7-33 Peptide Powder CAS 1818415-56-3

B7-33 Peptide is a synthetic single-chain analogue of the relaxin-2 B-chain, specifically engineered as a highly selective RXFP1 receptor agonist. Manufactured via standardized solid-phase peptide synthesis (SPPS), it retains accurate target binding activity and stable molecular structure, serving as a precise molecular tool for high-standard cardiovascular and fibrosis-related pharmacological research.

Distinct from conventional relaxin analogs with non-specific pathway activation, B7-33 Peptide exhibits strict signaling selectivity. It preferentially triggers the downstream ERK1/2 signaling cascade while eliminating undesired cAMP pathway activation. This unique selectivity effectively reduces experimental background interference, significantly improving mechanistic accuracy and reliability in fibrosis modeling and cardiovascular mechanism research systems.

1. Applied for mechanism research and functional verification of myocardial injury and cardiac fibrosis lesions.

2. Used to explore pathological progression and regulatory mechanisms of multi-organ fibrosis.

3. Enables precise exploration of RXFP1 receptor activation and relaxin signal cascades.

4. Suitable for target verification and efficacy screening in preclinical cardiovascular drug research.

■ All batches undergo standard purification and strict HPLC testing to guarantee high-purity, stable research-grade quality.

■ Complete batch documents including COA and HPLC reports are provided to meet global research audit standards.

■ Strict raw material control and standardized production ensure excellent batch consistency.

■ Moisture-proof and light-proof sealed packaging ensures stable quality during transport and storage.

■ All production and testing comply with international laboratory quality specifications.